Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesINVEX Therapeutics Ltd

INVEX Therapeutics Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.085 AUD -0.01 ( 5.56%)
Last update at 2026-11-11T03:47:00Z
VOLUME
4223
Market Cap
7.78M

Momentum Score

…

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of efficacious treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Perth, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.09
Low
0.09
High
52 Week Price Range
0.09
Low
0.15
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public disclosures for INVEX Therapeutics Ltd (IXC.AU) are limited, but company filings indicate it is an Australian-listed therapeutics company focusing on developing clinical-stage treatments. Long-term growth drivers may include successful clinical development, regulatory approvals, and commercialization of any approved therapies, which could support revenue and partnerships. Investors may find the company attractive for potential upside from clinical progress and addressing unmet medical needs.

Key risks include clinical and regulatory failure, ongoing financing and dilution risk common to small-cap biotechs, and limited public information that increases uncertainty.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.09
Dividend Yield
-
Revenue TTM
0.05M
Revenue Per Share
0.00
Gross Profit TTM
0.05M
Debt / Equity
-
ROE
-29.54%
Net Debt
-1.52M
ROCE
-39.50%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -1.40M -0.48M -2.85M -7.75M -3.95M
Net income -1.35M -0.48M -1.64M -7.75M -3.95M
Selling general administrative - 0.72M 1.17M 1.29M 0.90M
Selling and marketing expenses - 0.02M 0.14M - -
Gross profit - 0.23M 1.21M 0.46M 0.18M
Ebit - - -2.85M -17.53M -8.27M
Ebitda -1.54M - -0.72M -8.98M -4.24M
Depreciation and amortization - 0.71M 2.13M 8.55M 4.03M
Operating income -1.54M -0.71M -2.13M -8.55M -4.03M
Other operating expenses 1.54M 0.94M 3.35M 9.01M 4.22M
Interest expense - - - - 0.08M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.23M 0.49M 0.80M 0.08M
Net interest income - 0.23M 0.49M 0.80M 0.08M
Income tax expense -0.05M - -1.21M -9.34M -4.11M
Total revenue - 0.23M 1.21M 0.46M 0.18M
Total operating expenses 1.54M 0.94M 3.35M 8.98M 4.24M
Total other income expense net 0.15M 0.23M 0.49M 0.43M 0.21M
Net income from continuing ops - -0.48M -1.64M -7.75M -3.95M
Net income applicable to common shares - -0.48M -1.64M -7.75M -3.95M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 4.06M 5.47M 6.12M 22.80M 29.49M
Total liab 0.15M 0.22M 0.43M 1.57M 1.00M
Total stockholder equity 3.91M 5.25M 5.69M 21.23M 28.48M
Other current liab 0.02M - 0.43M 0.43M 0.87M
Common stock 22.41M - 22.41M 36.41M 36.41M
Capital stock - 22.41M - 36.41M 36.41M
Retained earnings -21.04M -19.70M -19.22M -17.58M -9.83M
Cash 1.52M 5.38M 6.03M 22.47M 29.34M
Total current liabilities 0.15M 0.22M 0.43M 1.57M 1.00M
Net debt -1.52M - -6.03M -22.47M -29.34M
Short term debt - - - 0.00M 0.00M
Other stockholder equity - - - -18.83M -26.58M
Total current assets 4.06M 5.47M 6.12M 22.80M 29.49M
Net tangible assets - - - - 28.48M
Short term investments 2.50M - - - -
Net receivables 0.05M - 0.09M 0.33M 0.15M
Accounts payable 0.13M 0.17M 0.01M 1.14M 0.14M
Accumulated other comprehensive income 2.53M - 2.50M 2.40M 1.90M
Non current assets total - 0.00M - 0.00M 0.00M
Long term debt total - - - 0.00M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - 0.00M - - -
Change to liabilities - - - - 0.35M
Total cashflows from investing activities -2.50M - - - -
Total cash from financing activities - 0.00M -14.00M 0.00M 0.00M
Net income -1.35M -0.48M -1.64M -7.75M -3.95M
Change in cash -3.86M -0.65M -16.45M -6.87M -3.38M
Begin period cash flow 5.38M 6.03M 22.47M 29.34M 32.72M
End period cash flow 1.52M 5.38M 6.03M 22.47M 29.34M
Total cash from operating activities -1.36M -0.65M -2.44M -6.87M -3.38M
Other cashflows from investing activities -2.50M - - - -
Change to account receivables -0.05M -0.00M 0.24M -0.19M -0.12M
Sale purchase of stock - - -14.00M 0.00M 0.00M
Other cashflows from financing activities - 0.00M -14.00M 0.00M 0.00M
Change to netincome - - - - 0.36M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital -0.05M -0.00M 0.24M -0.19M -0.12M
Stock based compensation - 0.02M 0.14M 0.48M 0.35M
Other non cash items 0.04M -0.19M -1.04M 0.59M 0.35M
Free cash flow -1.36M -0.65M -2.44M -6.87M -3.38M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
IXC
INVEX Therapeutics Ltd		 -0.01
5.56%		 0.09 - - 166.07 1.99 -1.33
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 -9.86

Profile*

INVEX Therapeutics Ltd

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of efficacious treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Perth, Australia.

101 St Georges Terrace, Perth, WA, Australia, 6000

61 8 6558 0886

https://www.invextherapeutics.com

Name Title Year Born
Ms. Narelle Warren B.Com., L.L.B., B.Com, LLB CFO & Company Sec. NA
Prof. Alexandra Jean Sinclair Exec. Director & Chief Scientific Officer NA
Dr. Thomas Duthy M.B.A., Ph.D. Exec. Director NA
Ms. Carol Parish Chief Operating Officer NA
Ms. Narelle Warren B.Com., L.L.B., B.Com, LLB CFO & Company Secretary NA
Dr. Thomas Duthy M.B.A., Ph.D. Executive Director NA
Ms. Narelle Warren B.Com., L.L.B., B.Com, LLB CFO & Company Secretary NA
Dr. Thomas Duthy M.B.A., Ph.D. Executive Director NA
Ms. Narelle Warren B.Com., L.L.B., B.Com, LLB CFO & Company Secretary NA
Dr. Thomas Duthy M.B.A., Ph.D. Executive Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…